SK Bioscience releases second batch of COVID-19 vaccines

By Kim, Jin-Gu | translator Alice Kang

22.02.09 12:05:20

가나다라 0

Will be manufacturing 40 million doses of Novavax’s COVID-19 vaccine this year after manufacturing 20 million doses of AstraZeneca’s vaccine last year

Has the capacity to manufacture up to 140million doses annually… plans to triple its capacity by 2026.

SK Bioscience announced that it had shipped its second batch of commercial COVID-19 vaccine products. By manufacturing vaccines for AstraZeneca and then Novavax, the industry's evaluation is that the company has well demonstrated its large-scale and stable manufacturing capacity.

SK Bioscience announced that it had shipped the first batch of Nuvaxovid from its L House in Andong, North Gyeongsang Province in the morning of the 9th. The released batch is predicted to be 840,000 doses of the vaccine that was approved for lot release by the Ministry of Food and Drug Safety the day before. SK Bioscience plans to ship out 2 million doses by the end of this month.

Also, the manufacturing amount

Kim, Jin-Gu(kjg@dailypharm.com)

If you want to see the full article, please JOIN US (click)